PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 24729214-3 2014 Treating R3327-AT1, Pgp-positive tumor cells at pH 7.4 with daunorubicin, cisplatin or docetaxel led to marked apoptosis induction and cell death. Daunorubicin 60-72 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 20-23 24729214-5 2014 Inhibiting Pgp with verapamil reversed the acidosis-induced chemoresistance against daunorubicin and docetaxel. Daunorubicin 84-96 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 11-14 24729214-10 2014 Since daunorubicin and docetaxel (but not cisplatin) are substrates of the Pgp, these results underline the influence of the tumor acidosis on the Pgp-mediated chemoresistance which can be counteracted by inhibition of the drug transporter. Daunorubicin 6-18 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 75-78 24729214-10 2014 Since daunorubicin and docetaxel (but not cisplatin) are substrates of the Pgp, these results underline the influence of the tumor acidosis on the Pgp-mediated chemoresistance which can be counteracted by inhibition of the drug transporter. Daunorubicin 6-18 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 147-150 18729196-2 2008 In vitro, extracellular acidosis (pH 6.6) activated p38 and ERK1/2 and thereby induced daunorubicin resistance via a pronounced activation of pGP. Daunorubicin 87-99 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 142-145 22035293-8 2011 P-glycoprotein function and drug sensitivity were analyzed by Daunorubicin accumulation and MTT assays. Daunorubicin 62-74 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 0-14 19499569-3 2010 Morin, phloretin, biochanin A, chalcone, and silymarin significantly increased DNM accumulation by greater than 2.5-fold, suggesting they are P-gp inhibitors. Daunorubicin 79-82 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 142-146 18729196-4 2008 Intracellular acidification also induced daunorubicin resistance via activation of pGP, which was mediated by activation of p38 alone. Daunorubicin 41-53 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 83-86 16199376-2 2005 In vitro, these biotinylated immunoliposomes were used to by-pass P-glycoprotein in multidrug-resistant RBE4 brain capillary endothelial cells and thereby to achieve 2- to 3-fold higher intracellular accumulation of liposomal daunomycin as compared to free drug. Daunorubicin 226-236 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 66-80 17072096-8 2006 In conclusion, for the first time we demonstrated that TA increases the intestinal absorption of P-gp substrates Rho123 and daunorubicin, possibly by modulating the P-gp function without changing the expression level of P-gp in the rat intestine. Daunorubicin 124-136 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 97-101 12820137-5 2003 The in vivo canalicular excretion clearance (CL(exc)) of daunomycin was also decreased by 79% (p < 0.01) in PCM rats, but the degree was more severe than would be expected from the 22% decrease in the expression of P-gp and the 33% decrease in the uptake of daunomycin (CL(int)). Daunorubicin 57-67 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 218-222 8944692-6 1996 Daunorubicin, vinblastine, etoposide, cyclosporin, and PSC-833, substrates/modulators of P-glycoprotein, were also potent inhibitors of E217G transport, and E217G competitively inhibited the ATP-dependent transport of daunorubicin. Daunorubicin 0-12 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 89-103 15618650-5 2002 Expression of P-gp was detected by immunocytochemistry, and efflux-directed transport of the P-gp substrate [(3)H]daunomycin was observed. Daunorubicin 114-124 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 93-97 9624121-0 1998 Wild-type p53-mediated induction of rat mdr1b expression by the anticancer drug daunorubicin. Daunorubicin 80-92 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 40-45 9624121-4 1998 Here, we report that the expression of the rat mdr1b can be induced by anticancer drug daunorubicin. Daunorubicin 87-99 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 47-52 9624121-5 1998 Further analysis identified a bona fide p53-binding site spanning from base pairs -199 to -180 (5"-GAACATGTAGAGACATGTCT-3") in the rat mdr1b promoter that is essential for basal and daunorubicin-inducible promoter activities. Daunorubicin 182-194 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 135-140 9523982-4 1998 The transport of daunomycin (DNM), a P-gp substrate, was used to study age-related functional differences in P-gp. Daunorubicin 17-27 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 37-41 9523982-4 1998 The transport of daunomycin (DNM), a P-gp substrate, was used to study age-related functional differences in P-gp. Daunorubicin 29-32 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 37-41 9523982-5 1998 DNM uptake in the presence of ATP was greater than uptake in the absence of ATP in both young and adult cLPM vesicles, showing that P-gp is functional in both groups. Daunorubicin 0-3 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 132-136 9626758-8 1997 The photoaffinity labeling as well as CyA transport by canalicular membrane vesicles were inhibited by CyA and the p-glycoprotein substrates daunomycin and PSC-833, but not by taurocholate, indicating that CyA is excreted by p-glycoprotein. Daunorubicin 141-151 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 115-129 9626758-8 1997 The photoaffinity labeling as well as CyA transport by canalicular membrane vesicles were inhibited by CyA and the p-glycoprotein substrates daunomycin and PSC-833, but not by taurocholate, indicating that CyA is excreted by p-glycoprotein. Daunorubicin 141-151 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 225-239 8944692-6 1996 Daunorubicin, vinblastine, etoposide, cyclosporin, and PSC-833, substrates/modulators of P-glycoprotein, were also potent inhibitors of E217G transport, and E217G competitively inhibited the ATP-dependent transport of daunorubicin. Daunorubicin 218-230 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 89-103 8944692-7 1996 C219, a monoclonal antibody against P-glycoprotein, inhibited ATP-dependent transport of E217G and daunorubicin but not of taurocholate or S-(2,4-dinitrophenyl)glutathione. Daunorubicin 99-111 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 36-50 8790221-0 1996 Carbon-11-labeled daunorubicin and verapamil for probing P-glycoprotein in tumors with PET. Daunorubicin 18-30 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 57-71 8877882-0 1996 Inhibitors of P-glycoprotein-mediated daunomycin transport in rat liver canalicular membrane vesicles. Daunorubicin 38-48 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 14-28 8877882-2 1996 Recent studies using isolated rat canalicular liver plasma membrane (cLPM) vesicles indicate that daunomycin (DNM) is a substrate for the ATP-dependent P-gp efflux system in the rat liver. Daunorubicin 98-108 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 152-156 8877882-2 1996 Recent studies using isolated rat canalicular liver plasma membrane (cLPM) vesicles indicate that daunomycin (DNM) is a substrate for the ATP-dependent P-gp efflux system in the rat liver. Daunorubicin 110-113 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 152-156 8877882-4 1996 The objective of this study was to examine the inhibitory effects of various organic compounds, most of which have been studied previously in MDR cancer cells, on P-gp-mediated [3H]DNM uptake into cLPM. Daunorubicin 181-184 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 163-167 8877882-10 1996 Phosphatidylcholine, a substrate for the gene product of the class III P-gp gene, produced significant inhibition of [3H]DNM transport (30.6% at a 10-fold-higher substrate concentration), suggesting that transport may be mediated, at least in part, by this P-gp gene product. Daunorubicin 121-124 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 71-75 8877882-10 1996 Phosphatidylcholine, a substrate for the gene product of the class III P-gp gene, produced significant inhibition of [3H]DNM transport (30.6% at a 10-fold-higher substrate concentration), suggesting that transport may be mediated, at least in part, by this P-gp gene product. Daunorubicin 121-124 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 257-261 8103798-8 1993 Agents that bind to P-glycoprotein, such as vinblastine, daunorubicin and reserpine, markedly inhibited the secretion of digoxin. Daunorubicin 57-69 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 20-34 7909523-5 1994 ATP-dependent transport of the permanently charged amphiphilic cations was inhibited by the P-glycoprotein inhibitors and substrates quinidine, verapamil, and daunorubicin. Daunorubicin 159-171 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 92-106 29238994-8 2018 KEY-FINDINGS: Compound 1 increased the DNA accumulation to 6.5-fold and decreased the DNM efflux to approximately 1/2 in the overexpressing P-gp cell line. Daunorubicin 86-89 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 140-144 1360981-11 1992 Verapamil competitively inhibited P-gp-mediated accumulation of [3H]daunomycin but failed to alter the fluidity of CMV. Daunorubicin 68-78 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 34-38 1360981-2 1992 P-gp has been localized to the apical plasma membrane of the bile canaliculus where it has been shown to transport [3H]daunomycin. Daunorubicin 119-129 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 0-4 1360981-3 1992 In this study, we investigated whether alterations in membrane lipid fluidity of canalicular membrane vesicles (CMV) could modulate the P-gp-mediated accumulation of [3H]daunomycin and [3H]vinblastine. Daunorubicin 170-180 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 136-140